-
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
-
Genetic Testing Gaps
Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling.
by Kate Yandell
-
Patient Advocates Tune in for Precision Medicine Primer
Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.
by Kevin McLaughlin
-
Liquid Biopsies May Ease Enrollment in Clinical Trials
A study shows that a blood test for gastrointestinal tumor mutations gave results in a third of the time needed for solid tissue testing. Patients who received the blood test were more likely to enroll in clinical trials.
by Emma Yasinski
-
Taking Drug Dosing Off Autopilot
Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.
by Marcus A. Banks
-
Targeted Therapy for Early-Stage Lung Cancer?
A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.
by Ashley P. Taylor
-
What is a Super Responder?
Researchers are investigating why certain patients have an exceptional response to a particular drug.
by Bradley Jones
-
Tumor Testing May Help Guide Pancreatic Cancer Treatment
For a small group of pancreatic cancer patients who were able to receive therapies targeting the molecular alterations in their tumors, these matched therapies were associated with longer life.
by Cheryl Platzman Weinstock
-
Despite Generic Imatinib, Cost of Treating CML Remains High
The arrival of generic versions of the targeted therapy imatinib only modestly reduced the cost of treating chronic myelogenous leukemia patients, a study finds.
by Anna Azvolinsky
-
New Drugs for an Elusive Cancer Target
Medical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.
by Anna Azvolinsky
Cancer Talk
Improving Communication for Deaf Cancer Patients
After a cancer diagnosis, people who are deaf or have hearing problems can struggle if accommodations don’t meet their communication needs.
by Eric Fitzsimmons
Is Immunotherapy Right for People Hospitalized With Advanced Cancer?Researchers find no evidence that immune checkpoint inhibitors benefit cancer patients getting inpatient care. They urge earlier consideration of palliative care.
by Kyle Bagenstose
Celebrity Cancer Stories Can Lack Important InformationNews coverage about public figures facing cancer frequently leaves out key details about the diagnosis and fails to provide background information on cancer.
by Laura Gesualdi Gilmore
AACR Annual Meeting 2025Immunotherapies, cancer vaccines and more from Cancer Today’s coverage of the AACR Annual Meeting 2025.